Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2025—A 68-year-old male with a history of multiple myeloma was discovered to have a 3-cm carotid body mass on PET/CT. Surgery was consulted and determined that the lesion was not amenable to surgery. Radiology favored the lesion to be a paraganglioma, so plasma metanephrine and normetanephrine were tested and were negative. With paraganglioma as the working diagnosis, germline genetic testing was performed.
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
September 2025—Leaders of the Digital Pathology Association met online with CAP TODAY publisher Bob McGonnagle to talk about digital pathology and much that’s related: adoption, investment, and artificial intelligence tools. “Most people are playing catch-up,” Marilyn Bui, MD, PhD, past president of the DPA and a member of the association’s board of directors, said of digital pathology. Of AI and digital pathology, DPA Foundation president Michael Rivers of Roche Tissue Diagnostics said, “Over the next several years we’re going to see a transformation in pathology.”
September 2025—Enrollment is underway now for a new CAP study that will make it possible for individual and integrated laboratories to compare inpatient analyte volumes and identify ordering practice problems. “This study is the first by the CAP that will allow system laboratories to evaluate a quality metric—inpatient test utilization—across all laboratories within their system and in comparison to like system laboratories across the U.S. and beyond,” says Richard Brown, MD, former chair and now advisor to the CAP Quality Practices Committee, whose members developed the study.
September 2025—It’s hard to believe that my two-year term as president of the CAP is already at its end. By the time you read this column, Jim Zhai, MD, will have been sworn in as our new president at the CAP annual meeting in Orlando. Serving as CAP president has given me amazing opportunities that I’m sure I would never have experienced otherwise. Perhaps the most rewarding has been the chance to meet hundreds of pathologists in the U.S. and across the globe and to witness firsthand the great work they’re doing for our profession, for the CAP, and particularly for our patients. The worldwide community of pathologists is truly impressive.
September 2025—Severe acute respiratory syndrome coronavirus 2 infection can lead to post-acute sequelae, or a condition known as long COVID. The World Health Organization defines long COVID as any symptoms that typically present within three months of acquiring COVID-19 and that persist for at least two months. Long COVID generally manifests as fatigue, pulmonary symptoms, and cognitive dysfunction. The biological mechanisms of long COVID are not well understood. Changes in the serotonin system may lead to cognitive changes, while mitochondrial changes may lead to fatigue, and complement and platelet activation to vascular disease.
September 2025—The efficacy of human epidermal growth factor receptor 2 antibody-drug conjugate therapy for treating HER2-low breast cancers necessitates more accurate and reproducible HER2 IHC scoring. The authors conducted a study to validate the performance and utility of a fully automated artificial intelligence (AI) solution for interpreting HER2 IHC in breast carcinoma. In the two-arm multireader study of 120 HER2 IHC whole slide images from four sites, four surgical pathologists assessed HER2 scoring with and without the aid of an AI solution. Both arms of the study were compared with high-confidence ground truth established by agreement of at least four of five breast pathology subspecialists according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 and 2023 guidelines. The mean interobserver agreement among the ground truth pathologists across all HER2 scores was 72.4 percent (n =120).
September 2025—When someone dies suddenly and unexpectedly, a forensic autopsy is often performed to identify the manner and cause of death. However, up to 30 percent of autopsies fail to identify any underlying anatomic or toxicologic etiologies, and the autopsy classification may be sudden unexplained death. This is particularly concerning in young people, in whom the cause could be an inherited genetic condition that could also affect family members. Therefore, postmortem genetic testing, also known as a molecular autopsy, may have utility in identifying underlying inherited diseases that could contribute to death. In many cases, sudden death is due to cardiac factors, but the type of cardiac dysfunction may depend on age.
September 2025
Q. Some of my laboratory staff are reluctant to reach out to the CAP with accreditation questions on checklist requirements because they fear that doing so will lead CAP inspectors to scrutinize those related items more closely during the next inspection. How does the College manage information from these phone calls? Read answer.
Q. An oncologist recently told me to perform a platelet count on a sodium citrate (blue top) tube even though the platelet results from the EDTA tube were valid—no platelet flags, a Q-flag value of zero, a normal platelet histogram, and no clumps seen on slide review. Based on this evidence, this patient is not an EDTA clumper and using the blue-top tube isn’t indicated or recommended, as far as I know. What is the science behind this request? There were platelet clumps in the blue-top tubes (platelet instrument flags and clumps seen on the slides from the citrate tubes), which further invalidated these results in my opinion as a licensed laboratory scientist. Read answer.
September 2025—In his previous role as a pathologist at Seattle’s Virginia Mason Medical Center, Dick Hwang, MD, PhD, was looking for a way to make his life—and his colleagues’ lives—easier. So he reached for something he hadn’t used in a while: his doctorate in computational biology. It was 2014, and Virginia Mason’s pathology group had just rolled out M*Modal Fluency Direct speech-recognition software as an optional tool for dictating diagnostic data. Dr. Hwang and many of his colleagues embraced the new software, but they soon realized that it meant they’d be spending a lot of time editing and formatting data. Entering a final diagnosis required, for example, typing “1.{tab}{caps lock},” dictating “cecum and ascending colon comma polypectomy,” then typing “:{caps lock}{return}{backspace}A.{tab}”—just as a start.
